Financial review 2025

The commitment and professionalism of Octapharma’s employees worldwide continue to underpin the company’s ability to serve patients reliably and deliver a strong, sustainable financial performance. Supported by these strengths, the Octapharma Group reported a strong performance in 2025.

Group sales increased by 5% year on year to a record €3.64 billion. Operating income rose by 8.5% to a new high of €577 million, supported by ongoing efficiency improvements and economies of scale in plasma collection and production.

Gross profit for the year reached €1.17 billion. Gross margin stood at 32.2%, slightly below the 32.7% reported in 2024. Income before tax increased to a record €554 million, compared with €534 million in the previous year, while net income was €453 million.

Operating cash flows strengthened over the year. Net cash from operating activities rose to €661 million, up from €542 million in 2024, highlighting the strength of the underlying business and disciplined financial management.

Operating expenses were broadly stable at €595 million, compared to €601 million in 2024. This included continued investment of €117 million in research and development. Together with capital expenditures of €331 million, we invested over €440 million in initiatives directed towards strengthening the portfolio, advancing the pipeline, and supporting future growth.

Recent investment continues to translate into efficiency gains across the organisation. Combined with significant raw plasma inventories, this provides a solid foundation for another robust performance in 2026.

Octapharma remains strongly profitable and well capitalised. The group’s focus remains on executing its long-term strategy, expanding into new markets, strengthening operational performance, and attracting and retaining talent to remain an employer of choice in a competitive industry.

Bold implementation and close collaboration across the organisation remain central to our success. I thank all employees for their continued commitment to Octapharma’s vision of providing new health solutions to advance human life all around the world.

Roger Mächler
Chief Financial Officer